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Abstract:
Prior to the 1990s, antipsychotic prescribing to children and adolescents was
uncommon, given the scarcity of safety data and the high risk of developing extrapyramidal
side effects.

The emergence of second generation antipsychotics, changes in the

epidemiology of pediatric mental health disorders, and expansion of antipsychotic drug use
have facilitated the uptake of pediatric prescribing. The speed at which these drugs are
being taken up by this vulnerable population is a concern.

From 2002 to 2008,

antipsychotic use in pediatric patients increased by 65% from 2.9 million to 4.8 million
prescriptions.1

Until 2006, all atypical antipsychotic prescribing was off-label, as these

drugs were not approved by the FDA for use among children and adolescents.

Using

national retail prescription data of children and adolescents ages 0-17 obtained from IMS
Health covering the years 2005-2008, the effect of the 2006 and 2007 FDA approvals of
Risperdal for specific pediatric use was examined using segmented interrupted time-series
regressions. The analysis reveals that the FDA approvals had a statistically significant
level effect but no trend effect on Risperdal prescribing. In addition, there was a stronger
level effect observed among non-mental health specialists compared to psychiatrists and
other mental health specialists.

The results of this study suggest that FDA pediatric

approvals have an important role in legitimizing and facilitating prescribing, as there are
some physicians who are reluctant to weigh the risks and benefits independently through
off-label prescribing.

1
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I. Background

Introduction
Over the past two decades, the use of antipsychotic prescriptions has changed from
treating adults with severe psychotic disorders to treating a wider range of disorders for a
more diverse population. This change in prescribing has led to exponential increases in
overall utilization and expenditure. As a result, spending on antipsychotic prescriptions is
roughly $13.1 billion annually, exceeded only by lipid regulators, proton pumps, and
antidepressants. Within the Medicaid program, antipsychotics have become the most costly
drug class, accounting for more than 15% of overall drug spending. (Crystal, Olfson, Huang,
Pincus, & Gerhard, 2009) Given these trends, it is becoming increasingly important to
consider the appropriateness and possible consequences of antipsychotic prescribing to this
new diverse population that now includes young children and adolescents. It is also equally
important to ask who is being prescribed these antipsychotics, by whom, and for what
reasons.

The origins of Antipsychotics
Antipsychotics (also referred to as neuroleptics) are a class of drugs used primarily to
manage psychotic symptoms such as hallucinations, delusions, and disorganized thinking
and behavior. (Ivanov & Charney, 2008) The first antipsychotic drug chlorpromazine
(marketed under the name Thorazine) originated from Paul Erhlich’s early work
researching the antimalarial effects of phenothiazine derivatives in the late 1800s. First
introduced in the late 1950s, the widespread use of chlorpromazine drastically reduced
psychiatric inpatient populations and stimulated the search for other phenothiazine
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derivatives. Between 1954 and 1975, 15 antipsychotic drugs were introduced in the United
States. These included haloperidol, thioridazine, thiothixene, loxapine, and trifluoperazine.
Despite their clinical benefit, these first generation antipsychotics were observed to have
relatively high risks of extrapyramidal symptoms (adverse neurological responses) that
include parkinsonism, dystonias, akathisia, and tardive dyskensia. (Shen, 1999) Given the
severity and intrusion of these side effects, these first generation antipsychotics were only
prescribed to adults with severe psychotic disorders in cases where the benefits clearly
outweighed the risk of extrapyramidal symptoms.
Beginning in the 1990s, a new drug, clozapine was introduced. Unlike previous
antipsychotic drugs, this particular drug was not only effective in reducing symptoms
associated with schizophrenia, but carried with it a lower risk of inducing extrapyramidal
symptoms. As a result, clozapine was labeled as an “atypical” antipsychotic; as it disproved
the assumption that extrapyramidal symptoms couldn’t be disentangled from the efficacy of
the first generation antipsychotics.

In addition, clozapine showed an increase in efficacy

for negative symptoms of schizophrenia, an increase in efficacy for treatment-refractory
patients, as well as a lower likelihood of raising serum prolactin levels. (Shen, 1999) The
actual pharmacological difference is that the primary mechanism for first generation
antipsychotics is mediated through the dopamine D2 receptor blockade, whereas “atypical”
antipsychotics (also known as second generation antipsychotics) use mixed dopamine
receptors.

(Surja, Tamas, & El-Mallakh, 2006) The success of clozapine led to the

development of several other similar antipsychotic drugs that include risperidone in 1994
(marketed as Risperdal), olanzapine in 1996 (marketed as Zyprexa), quetiapine in 1997
(marketed as Seroquel), ziprasidone in 2001 (marketed as Geodon), aripiprazole in 2002
(marketed as Abilify), and paliperidone in 2006 (marketed as Invega). (drugs@FDA.gov)
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The emergence of these “atypical” antipsychotics has had a tremendous influence in
broadening the use of antipsychotic prescriptions, primarily through off-label use.
reduction

of

extrapyramidal

symptoms

associated

with

these

second

The

generation

antipsychotics has facilitated the expansion of their use for a wider variety of clinical
indications and for a more diverse population including children and adolescents. Although
off-label prescribing is common practice, it is a concern for antipsychotic prescribing, as this
class of drugs still carries with it substantial risk. Despite its perceived clinical advantage
and safety, antipsychotic drug use has been associated with metabolic and developmental
side-effects among children and adolescents. Without substantial long-term safety data,
the use of these drugs should be more closely monitored. (Crystal, Olfson, Huang, Pincus, &
Gerhard, 2009)

Pediatric Mental Health and Use of Antipsychotics
As the use of antipsychotics have broadened, use among children and adolescents
has increased nearly two-fold over the past decade.

(America's State of Mind, 2011)

Schizophrenia, bipolar disorder, attention deficit disorders, and autism have been the
leading indications associated with the use of “atypical” antipsychotic prescriptions. (Chai,
Mehta, Moeny, & Governale, 2010) Changes in the identification of pediatric psychotic
disorders and the expansion of use in non-psychotic disorders that include ADHD and
autism have driven the uptake of these drugs among children and adolescents. (Ivanov &
Charney, 2008)
The diagnostic criteria for disorders such as schizophrenia and bipolar disorder as
defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) are based on
clinical presentations in adult populations, making it difficult to extrapolate a definitive
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diagnosis for a child or adolescent. Without a clear understanding of the psychopathology
of these psychotic disorders, clinicians have been reluctant in the past to diagnose children
and adolescents with these disorders, especially given the stigma and prognosis
implications attached to them. However, pediatric schizophrenia and bipolar disorder have
become increasingly accepted diagnoses as more and more individuals are diagnosed with
these conditions and retrospective studies provide validation and support. Furthermore,
the diagnostic criterion for these psychotic disorders has evolved with subsequent revisions
of the DSM. (Ivanov & Charney, 2008) As the inclusion criterion has broadened and the
diagnoses have become legitimized, a larger subset of the population has been captured
with these disorders. Over the last ten years, there has been a 40-fold increase in the
diagnosis of bipolar disorder among children and adolescents. (Moreno C. , Laje, Blanco,
Olfson, Jiang, & Schmidt, 2007)
Psychotropic drug use has become increasingly common in managing autism
spectrum disorders.

Otherwise referred to as ASD, autism spectrum disorders are a

collection of neuro-developmental disorders that are characterized by social and
communication deficits in addition to repetitive behavior.

It has been estimated that

between 30-60% of children and adolescents with ASD use at least one psychotropic
medication. (Mandell, Morales, Marcus, Stahmer, Doshi, & Polsky, 2008) Antipsychotics
have become accepted practices to treat irritability, aggression, and self-injury associated
with ASD.

Studies have found that haloperidol is effective in improving behavioral

symptoms in children with autism. However the high risk of extrapyramidal side effects
has limited its use to only the most severe and treatment resistant cases.

Atypical

antipsychotics are much more commonly used, given their reduced risk of extrapyramidal
side effects.

Antipsychotics are also being used to treat hyperactivity and stereotyped
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behavior associated with autistic disorders, despite lack of clinical efficacy data. (Posey,
Stigler, Erickson, & McDougle, 2008)

Although antipsychotic prescriptions such as

risperidone have been proven to be effective in reducing these behavioral symptoms, it is
unclear whether or not these drugs actually improve the social and communication
impairments characteristic of autism. Therefore it is necessary to consider the possibility
that these drugs are simply mitigating side effects, as opposed to addressing the core
problems.
Antipsychotics are also being prescribed to children and adolescents with ADHD, as
they have been shown to be effective in reducing aggression. A study looking at Medicaid
enrollees in the state of Tennessee found that 46% of antipsychotics prescribed were for
ADHD as a primary diagnosis. (Cooper, Fuchs, Arbogast, & Ray, 2004) In a national study
by the Office of Surveillance and Epidemiology at the FDA found that in 2009, the third
leading indication associated with the use of atypical antipsychotics among children and
adolescents was for attention deficit disorders. (Chai et al., 2010) The increase in the
percentage of antipsychotic prescribing for ADHD is a growing concern, as prescribing this
class of drugs to treat non-psychotic conditions remains controversial.

Further

complicating the trend in ADHD prescribing, is the high co-morbidity between ADHD and
pediatric bipolar. Some physicians have questioned the safety and efficacy of stimulants in
the treatment of children and adolescents with co-morbid ADHD/bipolar disorder. There
has been concern over whether or not long-term stimulant use induces mania and
psychosis. Given the complexity of differentiating between ADHD and bipolar, as well as
the lack of substantial knowledge about the efficacy and safety of prescribing combinations
of stimulants and antipsychotics (also referred to as poly-pharmacy), prescribing should be
done cautiously. (Moreno C. , Laje, Blanco, Jiang, Schmidt, & Olfson, 2007)
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Adverse Effects Associated with Pediatric Antipsychotic Use
Despite their clinical effectiveness in treating schizophrenia and bipolar disorder, as
well as managing aggression in non-psychotic disorders, antipsychotics still carry with
them substantial risk of side effects. Although atypical antipsychotics now represent the
majority of antipsychotic prescriptions, these second generation antipsychotics are not risk
free. Children are more likely than adults to develop extrapyramidal side effects with
risperidone and olanzapine.

In addition, children are at a higher risk of developing

withdrawal dyskinesia associated with the discontinuation of an atypical antipsychotic
drug.

(Ivanov & Charney, 2008)
Atypical antipsychotic use has also been associated in elevating levels of serum

prolactin, which can develop into hyperprolactinemia. Evidence suggests that this effect is
most pronounced in adolescents.

Hyperprolactinemia can lead to hypogonadism (low

estrogen in females and low testosterone in males), galatctorrhea, decreased libido, erectile
dysfunction, osteoporosis, and possible delay in puberty. (Wudarsky, Nicolson, &
Hamburger, 1999)

There is currently no research on the long-term effects of these

impairments on cognitive and physical development.
The metabolic risk associated with atypical antipsychotic use has been the most
concerning side effect. In an eight-week trial, participants prescribed risperidone gained an
average of 8 pounds, while participants prescribed olanzapine gained 13 pounds.

The

tendency to promote excessive weight gain has become the focus of ongoing pediatric trials,
as obesity poses serious health implications. Weight gain for example is associated with
elevated triglycerides and total cholesterol, as well as with metabolic syndrome and
diabetes mellitus.

Metabolic syndrome is characterized with abdominal obesity,

dyslipidemia, glucose intolerance, and hypertension.

(Ivanov & Charney, 2008)

This
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concern over metabolic effects was demonstrated when the FDA did not follow the Pediatric
Advisory Committee’s controversial recommendation to approve Geodon (ziprasidone) in
2009, as clinical trial data emerged revealing significant weight gain associated with
pediatric use. (drugs@FDA.gov)
Prescribing Discrepancies
Differential prescribing patterns of antipsychotic drugs to children and adolescents
raises concern over safety and access to proper mental health services. According to an
analysis of Medicaid and private insurance claims data, children and adolescents covered
by Medicaid were four times more likely to receive an antipsychotic medication in 2004
than those individuals with private insurance. ( (Crystal, Olfson, Huang, Pincus, &
Gerhard, 2009) In addition there has been concern over higher rates of antipsychotic
prescribing among foster kids. A 2011 study found that foster kids were more likely to
receive overlapping antipsychotic prescriptions and for longer durations than other kids
enrolled in Medicaid.

In addition, black foster children were more likely than white

children to be prescribed multiple antipsychotic drugs. (dosReis, Yoon, Rubin, Riddle, Noll,
& Rothbard, 2011)

Higher utilization among these vulnerable populations raises the

question whether or not these children and adolescents are accurately being diagnosed and
receiving the appropriate mental health care.

Most importantly, are these individuals

being placed at a higher risk, as antipsychotics have become a cost-effective and short-term
solution to mitigate larger systemic problems?
FDA Regulatory Activity
In an effort to address insufficient pediatric data on dosing, safety, and efficacy, the
FDA has used both a “carrot and stick” approach. In 1997, the Congress passed Section
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505A of the US Food and Drug Administration Modernization Act, providing an additional
6 months of patent protection or marketing exclusivity extension, in return for performing
studies specified by the FDA. The incentive program, also referred to as the Pediatric
Exclusivity Provision was renewed in 2002 and in 2007 as part of the Best Pharmaceutical
Children’s Act (BPCA).

In addition to using the “carrot” approach to encourage more

pediatric trials, the 2003 Pediatric Research Equity Act granted the FDA the authority to
require studies in children for a new drug likely to be used in pediatric populations. As a
result of these two approaches, the availability of pediatric data has substantially
increased, leading to over 100 labeling changes. (Vanchieri, Stith Buter, & Knutsen, 2008)
With the availability of more pediatric clinical trial data, the FDA approved the use
of risperidone in children and adolescents ages 5-16 for the treatment of autistic disorder on
October 6, 2006. This was the first pediatric approval for an atypical antipsychotic. Prior
to this approval, only haloperidol and thioridazine (both first generation antipsychotics)
were approved for children and adolescents. The following is a timeline of the current
pediatric approvals of atypical antipsychotics:

Risperdal (risperidone)
October 6, 2006:
Autistic disorder in children and adolescents ages 5-16
August 22, 2007:
Schizophrenia in adolescents ages 13-17
Short term treatment of manic or mixed episodes of bipolar
disorder in children and adolescents ages 10-17.
Abilify (aripiprazole)
November 29, 2007 Schizophrenia in adolescents ages 13-17
February 27, 2008 Short term treatment of manic or mixed episodes of bipolar
disorder in children and adolescents ages 10-17.
November 19, 2009 Autistic disorder in children and adolescents ages 6-17
Seroquel (quetiapine)
December 2009

Schizophrenia in adolescents ages 13-17
Short term treatment of manic or mixed episodes of bipolar
disorder in children and adolescents ages 10-17.
14

Zyprexa (olanzapine)
December 4 , 2009 : Schizophrenia in adolescents ages 13-17
Short term treatment of manic or mixed episodes of bipolar
disorder in children and adolescents ages 10-17.
FDA regulatory activity on already approved drugs can have a profound as well as
differential impact on the uptake and discontinuation of a drug.

(Gibbons, Brown, Hur,

Bhaumik, Erkens, & Herings, 2007) (Olfson, Marcus, & Druss, 2008) (Busch & Barry, 2009)
The FDA can positively impact utilization through new approvals and labeling changes,
and negatively impact utilization through the use of black-box warnings and advisories.
The majority of research that has primarily concentrated on the effect of warnings
and restrictions as opposed to approvals or labeling changes provides strong evidence for
the influence of FDA regulatory activity. The 2003 black-box warning on antidepressants
regarding increased risk of suicidal behavior among pediatric patients resulted in a
decrease in antidepressant use, demonstrating the influence of the FDA in conveying
information. In 2005, the FDA issued an advisory and a subsequent black-box warning on
the risk of atypical antipsychotic use among elderly patients with dementia. According to a
study using office-based physician data, mentions of atypical antipsychotics fell 2% overall
and 19% among those with dementia in the year following the advisories.

(Dorsey,

Rabbani, Gallagher, Conti, & Alexander, 2010) The decrease in atypical antipsychotic drug
use, especially among elderly dementia patients provide further support that FDA
regulatory activity is closely watched and has a profound impact on drug prescribing
trends. Given the strong response to both the black-box warnings that were issued for
pediatric antidepressant use and the warnings issued for elderly dementia patients, there is
reason to believe that physicians and patients are reactive to FDA regulatory activity.
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Objective
Although there have been several reports on the trends in antipsychotic prescribing
among children and adolescents, there have been no studies looking into how these trends
have been affected by the pediatric FDA approvals that began in 2006. Although drugs can
be prescribed off-label, having an approval for a specific indication or population not only
allows a drug to be marketed for a specific indication, but conveys a sense of safety by
condoning and legitimizing its use.

Given the complexity of pediatric mental health

disorders and the known safety risks associated with atypical antipsychotics, it is likely
that physicians might be hesitant to prescribe off-label. Therefore there it is hypothesized
that these approvals have contributed to the increase in pediatric antipsychotic prescribing
primarily among non-mental health specialists. This study will examine these assumptions
and fill the gaps in the literature on the effects of FDA regulatory activity on pediatric
prescribing trends.

II. Methods
To examine the effect of expanding FDA approvals to pediatric populations, this
study focuses on the prescribing trends of Risperdal (risperidone) among children and
adolescents ages 0-17 with respect to overall antipsychotic prescribing.

Using an

interrupted time series design, this study looked at the individual and combined effect of
the 2006 and 2007 FDA pediatric approval for the treatment of autism for individuals ages
5-17, Schizophrenia for individuals ages 13-17, and bipolar disorder for individuals ages 1017. A segmented regression analysis of interrupted time series data is the strongest, quasiexperimental design, as it can examine the immediate and long-term effects of the FDA
approvals on Risperdal prescribing. (Wagner et al., 2002)
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Data
Longitudinal data from IMS Health was used to look at antipsychotic prescribing
from 2005 to 2008.

The data set includes retail pharmacy prescriptions data for a

representative sample of children and adolescents ages 0-17 who filled an antipsychotic
prescription during the time period. This data set represents more than 60% of all annual
retail prescriptions filled in the US. Each prescription record contains a unique patient
identifier, data about the patient (date of birth and sex), the name of the drug, the dose, the
dispense date, the geographic location of where the prescription was written, a unique
physician id number, and payment type (i.e. private insurance or cash). This data set was
merged using the unique physician id numbers with a data set containing demographic
information on the providers that included specialty, age, and sex.
For the analysis, the raw data was collapsed to generate monthly counts of
Risperdal as well as all antipsychotic prescriptions written by each physician to create the
outcome variable. Two indicator variables were created for two FDA approval dates, as
well as two interaction terms between the interventions and time.

Month indicator

variables were created to account for time effects and indicator variables for physician
specialties were created to stratify the analysis.

Model Specifications
To examine the changes in Risperdal prescribing with respect to the two FDA
pediatric approvals in 2006 and in 2007, several segmented regression models were built
analyzing provider-month counts of Risperdal. For the first set of analyses, each
intervention was tested independently and then jointly. Each of the segmented regression
models were fitted using Poisson regression to model the mean number of Risperdal
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prescriptions written by each unique provider, offsetting for the total number of
antipsychotics prescribed per month with robust standard errors clustered around unique
physicians. Although there was no evidence of over dispersion, the segmented regression
models were also fitted using a negative binomial regression model as a robustness check.
In addition, since Rispderal was so commonly prescribed among clinicians, there was no
need to run a zero-inflated Poisson model.
Model 1a:
log

∗

∗

1

∗

1

Model 2a:
log

∗

∗

2

∗

2

∗

∗

1

∗

1

Model 3a:
log
∗

2

∗

2

Where:
 For each of the regressions, the average provider-month counts of Risperdal
prescriptions were modeled, offsetting for the average provider-month counts of total
antipsychotic prescriptions


is measured in t months beginning from January 2005



is an indicator variable where a value of 1 represents a prescription
that was written after the first approval date (October 2006)



is an interaction between time measured in months and
the first intervention dummy variable



is a dummy variable where a value of 1 represents a prescription
that was written after the second approval date (November 2007)



is an interaction between time measured in months and
the second intervention dummy variable.
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For the second set of analyses, 11 indicator variables to control for monthly time
effects were added to the model. April was chosen as the reference month since this month
reflects average prescribing.
Finally, to examine the differential effects due to physician specialty, the combined
models were analyzed by stratifying by pediatricians versus non-pediatricians and mental
health specialists versus non-mental health specialists.

The mental health specialists

consisted of psychiatrists, child psychiatrists, neurologists, and child neurologists. These
models were run with and without the month indicator variables.
To interpret the results of the interrupted time-series analyses, the pre- and postintervention slopes were plotted using the method of recycled predictions. This process
involved coding observations for each time period with a zero if they were before the
intervention or a 1 if they occurred after the intervention. (Liao, 1994) STATA version 11.2
was used to generate the predicated values as well as to run all of the statistical analyses.

III. Results
In each of the regressions, there were 1,494,366 observations representing the
monthly prescription counts of 140, 838 unique providers who wrote a least one
antipsychotic prescription to a child or adolescent ages 0-17 from 2005-2008. To highlight
the breakdown by specialty, 18.53% specialized in Family Medicine, 17.78% in Pediatrics,
14.66% in Psychiatry, and 7.51% in Internal Medicine. (Refer to Figure 1.2 and Table 1.3)
These unique providers prescribed a combined total of 1, 025, 773 prescriptions for
Risperdal in 2005, 1,245,078 in 2006, 1,337,050 in 2007, and 1,408,423 in 2008. (Refer for
Figure 1.1)

In addition, total antipsychotic prescribing volume was 2,335,727 in 2005,

2,910,539 in 2006, 3,097,803 in 2007, and 3,296,260 in 2008. (Refer to Table 1.1) Looking
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at total Risperdal prescribing by month, there appears to be seasonal trends, as evidenced
by the dip in the number of Risperdal prescriptions written in March. (Refer to Figure 1.1)
Looking at the regressions modeling each of the interventions separately show a
statistically significant effect of the FDA approvals on Risperdal prescribing. The October
2006 approval had a positive immediate effect on the level of Risperdal prescribing by
shifting up the percent of Risperdal prescribing by 1.31% points (refer to figure 2.1b). In
addition, there was a positive effect on the trend of Risperdal prescribing as the postintervention slope increased. The November 2007 approval also had an immediate effect on
the level of Risperdal prescribing by shifting up the percent of Risperdal prescribing by
1.04% points (refer to figure 2.2b). However the effect on trend was negative, as the postintervention slope decreased.
Although modeling the effects of each approval separately provides useful insight
into the short term effects of each approval, it is more accurate to model the approvals in a
combined model, especially since there is less than a year between the two interventions.
The results of the combined model show a positive effect on the level of Risperdal
prescribing by shifting up the percent of Risperdal prescribing by 2.44% points (refer to
figure 2.3b). In addition, the slope following the two FDA approvals remained the same as
the pre-intervention slope. Therefore the overall long-term effect of the FDA approvals had
a positive effect on the level of Risperdal prescribing, but did not have any effect on the rate
at which Risperdal lost market share from 2005-2008. In other words, the net effect of the
approvals provided an additional 24.4 months of market share that would have otherwise
would have naturally decayed due to loss of patent life, market competition, and loss of
novelty. This estimate was calculated using the pre-intervention slope to solve for the
number of months it would have taken for Risperdal to lose 2.44% points of market share.
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Stratifying the analyses by mental health specialists and non-mental health
specialists suggest that the FDA approvals had a differential impact on physician
prescribing by specialty. As hypothesized, there was a greater effect on non-mental health
specialists as the level of Risperdal prescribing shifted up 3.56% points versus 2.01% points
among specialists (refer to Figures 4.1b and 4.2b). In addition, stratifying the analysis by
Pediatricians and non-Pediatricians found that the level of Risperdal prescribing shifted up
by 4.02% points among Pediatricians versus 2.25% points among non-Pediatricians (Refer
to Figures 3.1b and 3.2b). Figure 5 in the appendix shows a comparison of these stratified
regressions in terms of the number of months of market share gained as a result of the FDA
approvals. It is clear from the histogram that Pediatricians were affected the most.

IV. Discussion
Limitations
Although the FDA labeling change had a statistically significant impact on
Risperdal prescribing trends, there are several factors that may have dampened the effects.
First, there is substantial evidence to suggest that the trend in the uptake of antipsychotic
drugs among children and adolescents began prior to the FDA labeling changes in 2006. In
the past decade, there have been several federal lawsuits against the leading antipsychotic
drug manufacturers under the False Claims Act for deceptive practices as well as several
state and individual class action law suits alleging off-label marketing. In 2009, Pfizer paid
$2.3 billion to settle allegations of illegally marketing Geodon, while Eli Lilly paid $1.4
billion to settle lawsuits against Zyprexa. In addition, Johnson and Johnson has paid $743
million to settle lawsuits alleging fraud and illegal marketing practices to pediatric and
elderly populations from 1999 to 2006. (Field, 2010) The effect of FDA labeling changes may
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have also been dampened by changes in the market for atypical antipsychotic drugs. During
this period, Invega, a similar atypical antipsychotic was introduced.

In addition to

competition from this new drug, pediatric approvals for Zyprexa (olanzapine), Seroquel
(quetiapine), and Abilify (aripiprazole) may have also affected Risperdal prescribing trends.
Alternatively, insurance coverage could have dampened the effect of FDA labeling changes.
Use of two and three-tier cost structures to steer consumers and physicians to choose either
lower cost or preferred drugs using price incentives may have impeded drug choice.
However this is highly unlikely, as there were no generic alternatives available prior to
2008.
Further interference in detecting the effect of the FDA labeling changes could be due
to the fact that Risperdal went off patent in October, 2008. Firms typically reduce their
allocation of marketing expenditures to drugs that are approaching the end of their patent
life. Although Risperdal did gain pediatric approval, the new labeling change might not
have been as heavily promoted since its patent was nearing expiration.

Therefore the

market share of Risperdal was already in decline due to competition from newer and more
heavily promoted drugs. In addition, if resources were not allocated to detailing and DTCA,
knowledge of the labeling changes to include pediatric populations would have been
diffused more slowly through FDA press releases, popular media, journals, and word of
mouth.
This study did not look at prescribing changes with respect to indication. It would
have been useful to look at whether the FDA approvals had differential effects based on
indication.

This would have allowed us to see whether or not physicians were closely

following FDA prescribing guidelines or merely interpreting the approvals as a broad
approval for pediatric use. In addition, by not looking at indications, this study is not able
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to determine whether or not the FDA approvals have facilitated the off-label prescribing of
antipsychotics for ADHD.
Lastly, this study focuses solely on Risperdal prescribing, rather than all 4 of the
antipsychotics that were approved for pediatric use. Looking the effects on these other
antipsychotics could have provided further evidence to strengthen the Risperdal findings.
In addition, this study focused on the effect of expanding antipsychotic labels. Therefore
the results of this study may not be applicable to other classes of drugs. It is very likely
that psychotropic drug prescribing patterns differ from other drug classes.

Implications
The results of this study clearly suggest that FDA labeling changes to include
pediatric populations had a significant impact on prescribing. Prior to the pediatric FDA
approval of Risperdal for autism, schizophrenia, bipolar disorder, all prescribing was offlabel. Given the complexity and difficulties in diagnosing pediatric mood disorders as well
as the risk of known and unknown adverse effects, it is reasonable to assume that
physicians without specific mental health training as compared to psychiatrists might have
been reluctant or less likely to prescribe antipsychotics to children and adolescents prior to
the approvals. The results of this study are consistent with this hypothesis and suggest
that physicians, especially those without specific mental health training rely heavily on the
FDA for guidance regarding safe and appropriate prescribing. Therefore it is extremely
important that pediatric approvals be made carefully, as they have the potential to have a
strong influence on utilization and prescribing trends.
For the pharmaceutical industry, the results of this study provide compelling
evidence to the value of conducting pediatric trials and thereby gaining drug approval for
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pediatric populations. The combined effect of the Risperdal approvals for pediatric use
resulted in shifting the market share of Risperdal prescribing by 2.44% points which is the
equivalent to retaining 24.4 months of market share.

More broadly, the uptake in

Risperdal in response to the FDA approvals in 2006 and 2007 reflects the influence of an
approval conveying safety and legitimacy.
Although this study only examined the impact of the FDA approval of Risperdal for
pediatric use, the increase in utilization and expenditure on antipsychotic drugs is most
likely attributable in large part to these approvals. Therefore future studies should focus
on assessing the magnitude of the effect of FDA approvals on the increase in expenditures
on antipsychotic drugs.

Conclusion
Using retail prescription pharmacy data, an interrupted time-series analysis was
used to look at the prescribing trends of Risperdal before and after the FDA approval for
pediatric use in 2006 and 2006. Given the results of this study that suggest FDA approvals
have a significant effect on the level of prescribing but no significant effect on trend, it is
extremely important to continue studying the effects of these approvals to determine
whether this response has been harmful or beneficial.

Given the discrepancy in

antipsychotic prescribing and the increasing off-label use for ADHD, there is suspicion to
believe that FDA approvals may be broadly interpreted as legitimizing use among children
and adolescents for all indications rather than for their specific approval.

This study

provides the first assessment of the effect of the FDA approval of antipsychotic drugs for
pediatric use and as well as a foundation for future studies.

24

References
(2011). America's State of Mind. Medco.
Busch, S. H., & Barry, C. L. (2009). Pediatric Antidepressant Use After the Black-Box
Warning. Health Affairs , 724-733.
Chai, G., Mehta, H., Moeny, D., & Governale, L. (2010). Atypical Antipsychotic Drug Use in
the US Outpatient Pediatric Population. FDA. Silver Spring: Office of Surveillance and
Epidemiology.
Cooper, W. O., Fuchs, C., Arbogast, P. G., & Ray, W. (2004). New Users of Antipsychotic
Medications Among Children Enrolled in TennCare. Arch Pediatr Adolesc Med , 158, 753759.
Crystal, S., Olfson, M., Huang, C., Pincus, H., & Gerhard, T. (2009). Broadened Use of
Atypical Antipsychotics: Safety, Effectivenesss, and Policy Changes. Health Affairs , 28 (5),
770-781.
Dorsey, E., Rabbani, A., Gallagher, S., Conti, R., & Alexander, C. (2010). Impact of FDA
Black Box Advisory on Antipsychotic Medication Use. ARCH INTERN MED , 170 (1), 96103.
dosReis, S., Yoon, Y., Rubin, D., Riddle, M., Noll, E., & Rothbard, A. (2011). Antipsychotic
Treatment Among Youth in Foster Care. Pediatrics , 128 (6), 1459-1466.
Field, R. I. (2010). Antipsychotic Medications are Spelling Legal Troule for Drugmakers.
Pharmacy and Therapeutics , 621-622.
Gibbons, R. D., Brown, H., Hur, K., Bhaumik, D. K., Erkens, J. A., & Herings, M. C. (2007).
Early Evidence on the Effects of Regulator's Suicidality Warnings on SSRI Prescriptions
and Suicide in Children and Adolescents. The American Journal of Psychiatry , 1356-1363.
Ivanov, I., & Charney, A. (2008). Treating Pediatric Patients with Antipsychotic Drugs:
Balancing Benefits and Safey. Journal of Translational and Personalized Medicine , 75 (3),
276-286.
Liao, T. F. (1994). Interpreting Probability Models: Logit, Probit, and Other Generalized
Linear Models. Newbury Park: Sage Publications.
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E.
(2008). Psychotropic medication use among medicaid-enrolled children with autism
spectrum disorders. Pediatrics , 121 (3), 441-448.
Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A., & Olfson, M. (2007). National
Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth. Arch Gen
Psychiatry , 64 (9), 1032-1039.
25

Moreno, C., Laje, G., Blanco, C., Olfson, M., Jiang, H., & Schmidt, A. (2007). National
Trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen
Psychiatry , 64 (9), 1032-1039.
Olfson, M., Marcus, S. C., & Druss, B. G. (2008). Effects of Fod and Drug Administration
Warnings on Antidepressant Use in a National Sample. Achives of General Psychiatry , 94101.
Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the
treatment of autism. The Journal of Clinical Investigation , 118, 6-14.
Shen, W. W. (1999). A History of Antipsychotic Drug Development. Comprehensive
Psychiatry , 40 (6), 407-414.
Surja, A. A., Tamas, R. T., & El-Mallakh, R. S. (2006). Antipsychotic medications in the
treatment of bipolar disorder. Current Drug Targets , 7, 1217-1224.
Vanchieri, C., Stith Buter, A., & Knutsen, A. (2008). Addressing Barriers to Pediatric Drug
Development. Washington, DC: National Academies Press.
Wudarsky, M., Nicolson, R., & Hamburger, S. D. (1999). Elevated Prolactin in Pediatric
Patients on Atypical Antipsychotics. J Child Adolesc Psychophamacol , 9, 239-245.

26

Table 1: Descriptive Statistics
Table 1.1 Annual Risperdal Prescribing

Year

Risperdal

All

Percent
Risperdal

2005
2006
2007
2008

1,025,773
1,245,078
1,337,050
1,408,423

2,335,727
2,910,539
3,097,803
3,296,260

43.92%
42.78%
43.16%
42.73%

Table 1.2 Physician Specialties

Specialty

Count

Percent

Family Medicine
Pediatrician
Psychiatrist
Internal Medicine
Nurse Practitioner
Family Practice
Child Psychiatrist
Physician Assistant
Emergency Room

26,098
25,046
20,652
10,579
9,574
6,993
5,631
4,415
4,163

18.53%
17.78%
14.66%
7.51%
6.80%
4.97%
4.00%
3.13%
2.96%

Other
Total

27,687
140,838

19.66%
100.00%
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Table 2
Individual and Combined Regression Models

(Number of Observations foe each Regression= 1,494,366)

Model 1a

Model 2a

Model 3b

Model 1b

Model 2b

Model 3b

-0.792634***

-0.813151***

-0.792634***

-0.795609***

-0.808780***

-0.796043***

month (B1)

-0.003364***
(.996642)

-0.001355***
(.998646)

-0.003364***
(.996642)

-0.002503***
(.997450)

-0.001132***
(.998868)

-0.002458***
(.997545)

intervention1
(B2)

-0.016017**
(.984110)

-0.069021***
(.933307)

-0.0209906
(.979228)

-0.078243***
(.924739)

t_aftr_intr1
(B3)

0.002299***
(1.00230)

0.004071***
(1.00408)

0.001957***
(1.001959)

0.003855***
(1.003863)

intercept (B0)

intervention2
(B4)

0.081631***
(1.08506)

0.130135***
(1.138982)

0.06461***
(1.066744)

0.126845***
(1.135241)

t_aftr_intr2
(B5)

-0.001549***
(.998646)

-0.003611***
(.996396)

-0.001103***
(.998897)

-0.003601***
(.996406)

jan (B6)

0.011627***
(1.011695)

0.011364***
(1.011429)

0.011840***
(1.011910)

feb (B7)

0.007554***
(1.007583)

0.007300***
(1.007327)

0.007625***
(1.007654)

mar (B8)

0.035308***
(1.035939)

0.036129***
(1.036789)

0.035486***
(1.036123)

may (B9)

-0.004004***
(.996004)

-0.003918***
(.996090)

-0.004044***
(.995964)

jun (B10)

-0.014656***
(.985451)

-0.014555***
(.985550)

-0.014781***
(.985328)

jul (B11)

-0.020231***
(.979973)

-0.019926***
(.980271)

-0.020421***
(.979787)

aug (B12)

-0.016392***
(.983742)

-0.015958***
(.984169)

-0.016688***
(.983451)

sep (B13)

-0.020007***
(.980192)

-0.026765***
(.973590)

-0.022312***
(.977935)

oct (B14)

-0.018840***
(.981336)

-0.025524***
(.974799)

-0.020409***
(.979798)

nov (B15)

-0.022931***
(.977330)

-0.023632***
(.976644)

-0.020392***
(.979815)

dec (B16)

-0.029057***
(.971361)

-0.028866***
(.971547)

-0.025987***
(.974348)

Incidence Rate Ratios are reported in parentheses
Asterisk denote statistical significance as follows:
∗∗∗
. ,
∗∗ .
.05,
∗ 0.05

0.1
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Table 3
Pediatricians vs. Non-Pediatricians

intercept
(B0)
month (B1)
intervention1
(B2)
t_aftr_intr1
(B3)
intervention2
(B4)
t_aftr_intr2
(B5)
jan (B6)
feb (B7)
mar (B8)
may (B9)
jun (B10)
jul (B11)
aug (B12)
sep (B13)
oct (B14)
nov (B15)
dec (B16)

Pediatricians
(n=284,100)

Pediatricians
(n=284,100)

-0.450248***
-0.0013218**
(.9987)
-0.114285***
(.8920)
0.0055165***
(1.0055)
0.1626727***
(1.1767)
-0.004901***
(.9951)

-0.446746***
-0.0010239*
(0.9990)
-0.102244***
(.9028)
0.0048781***
(1.0049)
0.1468148***
(1.1581)
-0.004318***
(.9957)
0.0006263
(1.0006)
0.0023173
(1.0023)
-0.004673
(.9953)
-0.0017373
(.9983)
-0.009228***
(.9908)
-0.011524***
(.9885)
-0.0054505
(.9946)
-0.014428***
(.9857)
-0.014348***
(.9858)
-0.014325***
(.9858)
-0.016638***
(.9835)

Incidence Rate Ratios are reported in parentheses
Asterisk denote statistical significance as follows:
∗∗∗
. ,
∗∗ .
.05,
∗ 0.05

NonPediatricians
(n=1,210,266)

NonPediatricians
(n=1,210,266)

-0.824682***
-0.0037959***
(.9962)
-0.0587775***
(.9429)
0.0036995***
(1.0037)
0.1251542***
(1.1333)
-0.003407***
(.9966)

-0.828795***
-0.002806***
(.9972)
-0.069481***
(.9329)
0.0034884***
(1.0035)
0.1231821***
(1.1311)
-0.003447***
(.9967)
0.0112047***
(1.0113)
0.0070959***
(1.0071)
0.0437541***
(1.0447)
-0.004315***
(.9957)
-0.015184***
(.9849)
-0.021774***
(.9785)
-0.019240***
(.9809)
-0.024247***
(.9760)
-0.021297***
(.9789)
-0.021647***
(.9786)
-0.027156***
(.9732)

0.1
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Table 4
Mental Health Specialist vs. Non-Mental Health Specialists
NonNonSpecialist
Specialist
Specialist
Specialist
(n=654,216)
(n=654,216)
(n=840,150)
(n=840,150)
intercept (B0)

-0.839572***

-0.843264***

-0.642437***

-0.645151***

month (B1)

-0.003664***
(.9963)

-0.002678***
(0.9973)

-0.0029700***
(.9970)

-0.002226***
(.9978)

intervetion1
(B2)

-0.049850***
(.9514)

-0.065297***
(.9368)

-0.1121815***
(.8939)

-0.097553***
(.9071)

t_aftr_intr1
(B3)

0.003308***
(1.0033)

0.03275***
(1.0033)

0.005636***
(1.0057)

0.004629***
(1.0046)

intervention2
(B4)

0.123704***
(1.1317)

0.125359***
(1.1336)

0.161353***
(1.1751)

0.140181***
(1.1505)

t_aftr_intr2
(B5)

-0.003392***
(.9966)

-003587***
(.9964)

-0.004559***
(.9954)

-0.003786***
(.9962)

jan (B6)

0.011234***
(1.0113)

.009524***
(1.0096)

feb (B7)

0.007004***
(1.0070)

0.007379***
(1.0074)

mar (B8)

-0.043129***
(1.0441)

0.022909***
(1.0232)

may (B9)

-0.005505***
(.9945)

0.000531
(1.0005)

jun (B10)

-0.016184***
(.9839)

-0.009117***
(.9909)

jul (B11)

-0.023108***
(.9772)

-0.013115***
(.9870)

aug (B12)

-0.020384***
(.9798)

-0.008770***
(.9913)

sep (B13)

-0.023869***
(.9764)

-021223***
(.9790)

oct (B14)

-0.020714***
(.9754)

-0.021819***
(.9784)

nov (B15)

-0.0216923***
(9785)

-0.018400***
(.9818)

dec (B16)

-0.026751***
(.9736)

-0.025538***
(.9748)

Incidence Rate Ratios are reported in parentheses
Asterisk denote statistical significance as follows:
∗∗∗
. ,
∗∗ .
.05,
∗ 0.05

0.1
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Table 5
Negative Binomial Regression Model
Poisson
Regression
Model
(n=1,494,366)
intercept (B0)
month (B1)
intervention1
(B2)
t_aftr_intr1
(B3)
intervention2
(B4)
t_aftr_intr2
(B5)
Jan (B6)
Feb (B7)
Mar (B8)
May (B9)
Jun (B10)
Jul (B11)
Aug (B12)
Sep (B13)
Oct (B14)
Nov (B15)
Dec (B16)

‐0.796043***
‐0.002458***
(.997545)
‐0.078243***
(.924739)
0.003855***
(1.003863)
0.126845***
(1.135241)
‐0.003601***
(.996406)
0.011840***
(1.011910)
0.007625***
(1.007654)
0.035486***
(1.036123)
‐0.004044***
(.995964)
‐0.014781***
(.985328)
‐0.020421***
(.979787)
‐0.016688***
(.983451)
‐0.022312***
(.977935)
‐0.020409***
(.979798)
‐0.020392***
(.979815)
‐0.025987***
(.974348)

Incidence Rate Ratios are reported in parentheses
Asterisk denote statistical significance as follows:
∗∗∗
. ,
∗∗ .
.05,
∗ 0.05

Negative
Binomial
Regression
(n=1,494,366
‐.760243***
‐.002220***
(.997782)
‐.089367***
(.914510)
.004087***
(1.004095)
.131239***
(1.140240)
‐.003767***
(.996240)
.013827***
(1.013923)
.007312***
(1.007339)
.0330077***
(1.033630)
‐.003999***
(.996010)
‐.014364***
(.985739)
‐.020330***
(.979876)
‐.0159996***
(.984131)
‐.020720***
(.979494)
‐.019926***
(.980271)
‐.019708***
(.980485)
‐.024816***
(.975490)

0.1
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Figure 1 Descriptive Statistics
(Figure 1.1 Count of Risperdal Prescribing by Month)

Risperdal
140000
120000
100000
80000
60000
Risperdal

40000
20000
0
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

The raw counts by month show an increase in the total number of Risperdal prescriptions
from 2005-2008. The obvious cyclical trends indicate the need to control for seasonal effects.

(Figure 1.2 Percent Market Share by Month)

Pct_Risperdal
0.48
0.46
0.44
0.42

Pct_Risperdal

0.4
0.38
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

There appears to be a decrease in the market share of Risperdal from 2005-2008. The cyclical
pattern seems to suggest that there is a distinct season effect in Risperdal prescribing
compared to all other antipsychotic prescribing.
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(Figure 1.3 Physician Specialties)

Distribution of Physcian Specialties

Other
Emergency Room
Physician
Assistant

Family Medicine

Pediatrician

Child Psychiatrist
Family Practice
Psychiatrist
Nurse
Practitioner
Internal Medicine
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Individual and Combined Regression Models
Figure 2.1a October 2006 Approval

Model 1a
0.46
0.44
0.42
0.4

With Approval

0.38

Without Approval

0.36
0.34
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 23: 1.57%

*Dashed line refers to the intervention (October 2006 FDA approval)

Figure 2.1b October 2006 Approval with month dummies

Model 1b
0.46
0.45
0.44
0.43
0.42
0.41
0.4
0.39
0.38
0.37

With Approval
Without Approval

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 23: 1.04%

*Dashed line refers to the intervention (October 2006 FDA approval)
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Individual and Combined Regression Models
Figure 2.2a November 2007 Approval

Model 2a
0.445
0.44
0.435
0.43
0.425
0.42
0.415
0.41
0.405
0.4

With Approval
Without Approval

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 1.31%

*Dashed line refers to the intervention (November 2007 FDA approval)

Figure 2.2b November 2007 Approval with month dummies

Model 2b
0.45
0.445
0.44
0.435
0.43

With Approval

0.425

Without Approval

0.42
0.415
0.41
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 1.23%

*Dashed line refers to the intervention (November 2007 FDA approval)
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Individual and Combined Regression Models
Figure 2.3a Combined Model

Model 3a
0.46
0.44
0.42
0.4

Without Approvals

0.38

With Approvals

0.36
0.34
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 3.20%

*Dashed lines refer to the interventions (FDA approvals)

Figure 2.3b Combined Model with month dummies

Model 3b
0.46
0.45
0.44
0.43
0.42
0.41
0.4
0.39
0.38
0.37

Without Approvals
With Approvals

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 2.44%

*Dashed lines refer to the interventions (FDA approvals)
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Pediatricians vs. Non-Pediatricians
(Figure 3.1a Pediatricians)

Pediatricians
0.66
0.65
0.64
0.63
0.62
0.61
0.6
0.59
0.58
0.57

With Approval
Without Approvals

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 4.34%

*Dashed lines refer to the interventions (FDA approvals)

(Figure 3.1b Pediatricians with month dummies)

Pediatricians
0.67
0.66
0.65
0.64
0.63
0.62
0.61
0.6
0.59
0.58

With Approval
Without Approvals

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 4.02%

*Dashed lines refer to the interventions (FDA approvals)
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Pediatricians vs. Non-Pediatricians
(Figure 3.2a Non-Pediatricians)

Non‐Pediatricians
0.46
0.44
0.42
0.4
0.38

With Approvals

0.36

Without Approvals

0.34
0.32
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 3.06%

*Dashed lines refer to the interventions (FDA approvals)

(Figure 3.2b Non-Pediatricians with month dummies)

Non‐Pediatricians
0.44
0.43
0.42
0.41
0.4
0.39
0.38
0.37
0.36
0.35

With Approvals
Without Approvals

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 2.25%

*Dashed lines refer to the interventions (FDA approvals)
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Mental Health Specialists
(Figure 4.1a: Non-Mental Health Specialists)

Non‐Specialists
0.54
0.52
0.5
0.48

With Approvals

0.46

Without Approvals

0.44
0.42
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 4.22%

*Dashed lines refer to the interventions (FDA approvals)

(Figure 4.1b: Non-Mental Health Specialists with month dummies)

Non‐Specialists
0.53
0.52
0.51
0.5
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0.45
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With Approvals
Without Approvals

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 3.56%

*Dashed lines refer to the interventions (FDA approvals)
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Mental Health Specialists
(Figure 4.2a: Mental Health Specialists with month dummies)

Specialists
0.44
0.42
0.4
0.38

With Approvals

0.36

Without Approvals

0.34
0.32
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47
Month

Difference at Month 32: 2.82%

*Dashed lines refer to the interventions (FDA approvals)

(Figure 4.2b: Mental Health Specialists with month dummies)
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Difference at Month 32: 2.01%

*Dashed lines refer to the interventions (FDA approvals)

40

Figure 5: Effect of the Combined FDA Approvals
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